AU6653698A - Use of the p-ten suppressor gene in diagnosis and treatment of cancer - Google Patents

Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Info

Publication number
AU6653698A
AU6653698A AU66536/98A AU6653698A AU6653698A AU 6653698 A AU6653698 A AU 6653698A AU 66536/98 A AU66536/98 A AU 66536/98A AU 6653698 A AU6653698 A AU 6653698A AU 6653698 A AU6653698 A AU 6653698A
Authority
AU
Australia
Prior art keywords
diagnosis
cancer
treatment
suppressor gene
suppressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66536/98A
Inventor
Ramon E. Parsons
Michael H Wigler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University of New York
Original Assignee
Columbia University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University of New York filed Critical Columbia University of New York
Publication of AU6653698A publication Critical patent/AU6653698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
AU66536/98A 1997-02-07 1998-02-06 Use of the p-ten suppressor gene in diagnosis and treatment of cancer Abandoned AU6653698A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3694397P 1997-02-07 1997-02-07
US60036943 1997-02-07
PCT/US1998/002615 WO1998034624A1 (en) 1997-02-07 1998-02-06 Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
AU6653698A true AU6653698A (en) 1998-08-26

Family

ID=21891553

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66536/98A Abandoned AU6653698A (en) 1997-02-07 1998-02-06 Use of the p-ten suppressor gene in diagnosis and treatment of cancer

Country Status (4)

Country Link
EP (1) EP1023076A4 (en)
AU (1) AU6653698A (en)
CA (1) CA2280097A1 (en)
WO (1) WO1998034624A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
US6777439B2 (en) * 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
WO2004074459A2 (en) * 2003-02-19 2004-09-02 Georgetown University Pten-deficient cells and their uses
CN109022461B (en) * 2017-06-08 2022-01-14 中山大学附属第一医院 Upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and application of encoded polypeptide thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262242B1 (en) * 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3

Also Published As

Publication number Publication date
EP1023076A4 (en) 2001-11-21
CA2280097A1 (en) 1998-08-13
WO1998034624A1 (en) 1998-08-13
EP1023076A1 (en) 2000-08-02

Similar Documents

Publication Publication Date Title
GB9903841D0 (en) Diagnosis and treatment of cancer
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
AU2002243495A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU4473596A (en) Methods of human prostate cancer diagnosis
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
AU1810899A (en) Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU9565598A (en) Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
AU6435398A (en) Prevention and treatment of hepatocellular cancer
AU2749395A (en) Medical use of bromelain
AU3760400A (en) Methods and reagents for the diagnosis and treatment of multiple sclerosis
GB9811598D0 (en) Diagnosis and treatment of cancer
AU2418499A (en) Org-5222 in the treatment of depression
AU7058000A (en) 13 human colon and colon cancer associated proteins
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU7260098A (en) Diagnosis and treatment of phosphatase 0r kinase-related disorders
AU5293198A (en) Promoter of the human endoglin gene and its use
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
AU5946999A (en) Tumour therapy and imaging
AU5871898A (en) Microparticles and their use in cancer treatment
AU9358398A (en) Use of p-glycoprotein (pgp) inhibitors in the treatment of cancer
AU8282498A (en) A senescence gene and its use in the treatment of cancer and other diseases